• Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors | Morningstar

    المصدر: Buzz FX / 18 سبتمبر 2024 10:06:12   America/New_York


    [GlobeNewswire](/news/globe-newswire) Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors SON-1010 is a targeted immune activation cancer therapy de
    Read more...
شارك على،